logo
Plus   Neg
Share
Email
Comment

Abeona Therapeutics (ABEO) Has Fallen To A 5-Month Low

Abeona Therapeutics (ABEO) announced Monday morning that it has been granted orphan drug designation by the FDA for its ABO-202 program, for the treatment of infantile Batten disease.

Abeona Therapeutics has been declining since the open Monday and is now down 1.05 at $13.02. The stock has dropped to a 5-month low.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT